[Cervical cancer screening in Switzerland - current practice and future challenges]

Area of Science:

• Oncology
• Public Health
• Gynecology

Context:

• Cervical cancer was a leading cause of cancer death in women at the start of the 20th century.
• The introduction of the Papanicolau (Pap) test in the 1960s led to a significant decline in cervical cancer mortality.
• Current cervical cancer prevention relies heavily on Pap smear screening, with human papillomavirus (HPV) testing and co-testing options now available.

Purpose:

• To compare current cervical cancer screening guidelines in Switzerland with those in other European countries.
• To evaluate the need for updating existing screening protocols in light of advancements in HPV testing and vaccination.

Summary:

• The article reviews cervical cancer screening practices and guidelines across European nations, with a specific focus on Switzerland.
• It highlights the historical success of the Pap test in reducing cervical cancer incidence and mortality.
• The potential of human papillomavirus (HPV) testing and vaccination as complementary or alternative screening strategies is discussed.

Impact:

• The findings suggest that current cervical cancer screening guidelines require revision to incorporate newer technologies like HPV testing and vaccination.
• Updating screening protocols can optimize cervical cancer prevention efforts.
• A review of both screening test choices and the overall organization of cervical cancer screening programs is recommended.